Testing a Long-Acting Acromegaly Treatment
Part of Hormones & metabolism clinical trials.
This trial tests whether octreotide long-acting injection—a medication that lowers growth hormone and IGF-1 levels—can effectively control acromegaly symptoms. Acromegaly is a condition where the body makes too much growth hormone, causing abnormal growth. This study aims to confirm the treatment works safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old
- You have active acromegaly with elevated growth hormone (GH ≥ 2.5 ng/mL) and high IGF-1 levels (index ≥ 1.3)
- You have not had pituitary surgery in the past 6 months and are not planning surgery or radiation during the study
- You have not received long-acting acromegaly medications (like long-acting octreotide or lanretide) within 3 months
- Your blood sugar (HbA1c) is 8.5% or lower
- You have not previously failed octreotide or lanretide therapy or had severe side effects from these drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
This trial tests if a ketogenic (very low-carb) diet can help lower IGF-I levels in people with acromegaly who are already on stable medication. If you have acromegaly and your IGF-I levels are still above normal despite treatment, this diet might offer an additional way to manage your condition.
Hear when a new Diagnosed With Acromegaly, Currently in the Active Stage of the Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.